Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Buti · SciRah

Researcher profile · Semantic Scholar

S. Buti

Share profile

S. Buti — researcher profile on SciRah

h-index: 45
Works: 549
Citations: 7,545

Most-cited papers

Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial
Serena Porcari, C. Ciccarese, V. Heidrich, D. Rondinella +29 more
2026Nature Medicine52 citations Open access
Semantic Scholar
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
G. Roviello, J. Molina-Cerrillo, F. Massari, L. Cerbone +22 more
2025Cancer Immunology and Immunotherapy19 citations Open access
Semantic Scholar
Host-related Determinants of Response to Immunotherapy in Non-small Cell Lung Cancer: The Interplay of Body Composition, Metabolism, Sex and Immune Regulation
Valentina Santo, L. Brunetti, Federica Pecci, M. Peroni +7 more
2025Current Oncology Reports14 citations
Semantic Scholar
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
R. M. Kopp, F. Massari, E. Grande, Timothy Schieber +31 more
2025Cancer Immunology and Immunotherapy12 citations Open access
Semantic Scholar
Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience
M. Rizzo, Franco Morelli, Y. Ürün, S. Buti +21 more
2025Cancer Medicine10 citations Open access
Semantic Scholar
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
C. Porta, F. Massari, T. Taha, E. Grande +27 more
2025Cancer Immunology and Immunotherapy10 citations Open access
Semantic Scholar
Unraveling the link between cholesterol and immune system in cancer: from biological mechanistic insights to clinical evidence. A narrative review.
Federica Pecci, V. Cognigni, G. C. Giudice, F. Paoloni +13 more
2025Critical reviews in oncology/hematology10 citations
Semantic Scholar
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study.
F. Massari, V. Mollica, R. M. Kopp, E. Grande +35 more
2025European Urology Focus9 citations
Semantic Scholar
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study
Giulia Airò, A. Guida, A. Gili, A. Signori +16 more
2025Journal of Kidney Cancer and VHL7 citations
Semantic Scholar
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
M. Santoni, G. Roviello, E. Grande, U. de Giorgi +32 more
2025Cancer Immunology and Immunotherapy6 citations Open access
Semantic Scholar
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.
Francesco Massari, M. Rosellini, B. Melichar, E. Grande +29 more
2025JCO Global Oncology6 citations Open access
Semantic Scholar
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
V. Mollica, F. Massari, Kazutoshi Fujita, P. Giannatempo +27 more
2026Cancer Immunology and Immunotherapy5 citations Open access
Semantic Scholar
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset
A. Rizzo, A. Zayed, E. Vitale, S. Buti +20 more
2025Clinical and Experimental Metastasis5 citations
Semantic Scholar
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
M. Bourlon, Luca Galli, E. Grande, Se Hoon Park +27 more
2025Frontiers in Oncology5 citations Open access
Semantic Scholar
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: technical aspects and primary staging setting
M. Bauckneht, L. Evangelista, Luca Sofia, M. Maccauro +338 more
2025Clinical and translational imaging5 citations Open access
Semantic Scholar
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review
G. C. Giudice, M. Maffezzoli, Irene Testi, Alessandro Acunzo +7 more
2025Expert Review of Anticancer Therapy5 citations
Semantic Scholar
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy
Federica Pecci, G. Mazzaschi, A. Dodi, P. Tamarozzi +15 more
2026Journal for ImmunoTherapy of Cancer4 citations
Semantic Scholar
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma.
V. Murianni, M. Campione, Malvina Cremante, U. Basso +18 more
2025Journal of Geriatric Oncology4 citations
Semantic Scholar
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations.
M. Corianò, A. Lazzarin, M. Maffezzoli, M. Santoni +26 more
2025Immunotherapy4 citations
Semantic Scholar
External Validation of the GRade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma
M. Maffezzoli, A. Signori, Davide Campobasso, G. C. Giudice +4 more
2025Technology in Cancer Research and Treatment4 citations Open access
Semantic Scholar
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
L. Incorvaia, S. Scagliarini, F. S. Marques Monteiro, Hideki Takeshita +26 more
2025Scientific Reports4 citations Open access
Semantic Scholar
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study
O. Fiala, S. Buti, Kazutoshi Fujita, A. G. de Liaño +29 more
2025Clinical and Experimental Metastasis4 citations Open access
Semantic Scholar
The Role of Circulating Tumor DNA in Patients Treated with Adjuvant Immune Checkpoint Inhibitors: Clinical Reality or Distant Horizon?
M. Maffezzoli, Ria Nagpal, M. Elewaily, L. Pedapati +5 more
2025Current Oncology Reports4 citations
Semantic Scholar
Microplastics as both a driver of genitourinary cancers and a deliverer of treatments
K. Sridharan, B. Maiorano, F. Rehan, F. Maradonna +7 more
2026Communications Medicine3 citations Open access
Semantic Scholar
Toxicity‐related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune‐based combinations (ARON‐1 study)
J. Molina-Cerrillo, G. Roviello, M. Bourlon, H. Študentová +26 more
2025International Journal of Cancer3 citations Open access
Semantic Scholar
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab.
G. C. Giudice, S. E. Rebuzzi, G. Mazzaschi, Federica Pecci +10 more
2025Cancer Treatment and Research Communications3 citations Open access
Semantic Scholar
Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations
S. E. Rebuzzi, A. Ghose, S. Rudman, B. Venugopal +65 more
2026The Oncologist2 citations Open access
Semantic Scholar
2658eP Prognostic validation of the meet-URO score compared with the IMDC score in metastatic renal cell carcinoma (mRCC) patients receiving first-line systemic treatment (Meet-URO 33 study)
S. E. Rebuzzi, S. Buti, E. Verzoni, A. Di Marco +16 more
2025Annals of Oncology2 citations Open access
Semantic Scholar
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
O. Fiala, F. Grillone, Kazutoshi Fujita, Enrique Grande +28 more
2025European Urology Open Science2 citations Open access
Semantic Scholar
The role of circulating kidney injury molecule-1 (KIM-1) in metastatic renal cell carcinoma (mRCC): A biomarker analysis of Tide-A, a phase 2 study of first-line avelumab (ave) plus intermittent axitinib (axi).
C. Ciccarese, A. Agostini, M. Panebianco, S. Buti +16 more
2025Journal of Clinical Oncology2 citations Open access
Semantic Scholar
The Italian hospital medical profession is broken too
S. Buti, G. Fornarini
2025The Lancet Regional Health - Europe2 citations
Semantic Scholar
A prospective external validation of the GRade, Age, Nodes and Tumor score in the ECOG-ACRIN EA8143 PROSPER trial
S. Buti, Se-Eun Kim, M. Maffezzoli, M. Allaf +5 more
2026The Oncologist1 citations
Semantic Scholar
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings
Matteo Bauckneht, L. Evangelista, Luca Sofia, M. Maccauro +338 more
2026Clinical and translational imaging1 citations Open access
Semantic Scholar
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study
M. Maffezzoli, A. Signori, Alessandro Acunzo, S. Buti +39 more
2026Cancer Immunology and Immunotherapy1 citations Open access
Semantic Scholar
Assessment of Bone Metastases, Skeletal-Related Events and Bone-Targeting Agents in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Systemic Therapy (Meet-URO 33 Study Subanalysis).
A. A. Valsecchi, S. E. Rebuzzi, M. Cursano, F. Pantano +44 more
2026Clinical Genitourinary Cancer1 citations Open access
Semantic Scholar
When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma.
S. Buti, B. D. Valle, Alessandro Acunzo, P. Tuttobene +6 more
2026Critical reviews in oncology/hematology1 citations Open access
Semantic Scholar
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
L. Cerbone, G. Roviello, Fabio Calabrò, T. Taha +27 more
2026Frontiers in Immunology1 citations Open access
Semantic Scholar
PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making
Francesco Esperto, A. Pischetola, M. Bauckneht, Jacopo Passoni +7 more
2026Cancers1 citations Open access
Semantic Scholar
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)
E. Beas-Lozano, S. Scagliarini, P. Valdez-Sandoval, María Fernanda Esparza-Orozco +21 more
2026Frontiers in Immunology1 citations Open access
Semantic Scholar
Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors
Giulia Bruschi, F. Paoloni, Federica Pecci, Elisabetta Tola +24 more
2026Scientific Reports1 citations Open access
Semantic Scholar
International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma
A. Rametta, S. Buti, M. Stellato, M. Maruzzo +17 more
2026Tumori1 citations Open access
Semantic Scholar
Lateral Deviation of the Tongue in an Otherwise Asymptomatic Patient
G. Ghidini, Alessandro Olivari, S. Buti, P. Vescovi +1 more
2025Oral Diseases1 citations Open access
Semantic Scholar
599TiP SELECTIO-UC STUDY: Prospective evaluation of the DDR genes alteration to predict response to platinum-based chemotherapy in advanced urothelial cancer
C. Ligato, C. Ciccarese, P. Zucali, M. Maruzzo +16 more
2025Annals of Oncology1 citations
Semantic Scholar
Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review
G. Iovane, Luca Traman, M. Maffezzoli, G. Fornarini +4 more
2025Oncology Research1 citations Open access
Semantic Scholar
The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review
M. Maffezzoli, G. C. Giudice, G. Iovane, M. Manini +7 more
2025Oncology Research1 citations
Semantic Scholar
3105P Sex-associated outcomes and Nectin-4 expression in Enfortumab Vedotin-treated advanced urothelial carcinoma
T. Taha, A. Alpert, J. Baranseh, E. Grande +11 more
2025Annals of Oncology1 citations Open access
Semantic Scholar
EP.11.05 Prognostic Value of Hb/RDW and Its Correlation With Immune-Inflammatory Profile in NSCLC Receiving First-Line Immunotherapy
F. Pecci, G. Mazzaschi, A. Dodi, P. Tamarozzi +13 more
2025Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.
M. Rizzo, Andrey Soares, Shilpa Gupta, Fabio Calabrò +21 more
2025JCO Global Oncology1 citations Open access
Semantic Scholar
362P: LIPI score in advanced NSCLC treated with ICIs: Prognostic impact and blood immune-inflammatory correlations
M. Manini, F. Pecci, G. Mazzaschi, A. Dodi +12 more
2025Journal of Thoracic Oncology1 citations
Semantic Scholar
228eP ABCA1 and ABCG1 cholesterol transporters expression on metastatic renal cell carcinoma, blood cholesterol and triglycerides, CONUT score: Impact on immunotherapy outcomes (CHOMET study)
G. C. Giudice, M. Maffezzoli, G. Mazzaschi, P. Tuttobene +12 more
2025Annals of Oncology1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Santoni×20
Invite
M. Santoni — researcher profile on SciRah
F. Massari×19
Invite
F. Massari — researcher profile on SciRah
O. Fiala×16
Invite
O. Fiala — researcher profile on SciRah
J. Molina-Cerrillo×15
Invite
J. Molina-Cerrillo — researcher profile on SciRah

×15

Invite

M. Maffezzoli — researcher profile on SciRah

G. Fornarini×14

Invite

G. Fornarini — researcher profile on SciRah

Andrey Soares×13

Invite

Andrey Soares — researcher profile on SciRah

Invite

M. Bourlon — researcher profile on SciRah

F. S. Monteiro×11

Invite

F. S. Monteiro — researcher profile on SciRah

S. E. Rebuzzi×11

Invite

S. E. Rebuzzi — researcher profile on SciRah

G. Roviello×10

Invite

G. Roviello — researcher profile on SciRah

Invite

Y. Ürün — researcher profile on SciRah